CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 118 enrolled
Drug / intervention
600 mg ibuprofen three times daily for 48 weeks +1 moredrug
Likely dose
600 mg ibuprofen three times daily for 48 weeksfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02006576
NCT02006576Phase 2Completed
CompareCT.gov

Proof-of-concept Study to Demonstrate Inhibition of Prostaglandin E (PGE) Production and Associated Biological Effects in the Lower Respiratory Tract by Ibuprofen.

University of Nebraska·interventional·Posted Dec 10, 2013·Updated Dec 13, 2023

In Brief

A Phase 2 clinical trial evaluating 600 mg ibuprofen three times daily for 48 weeks and Placebo three times daily for Emphysema. Completed, enrolled 118 participants across 5 sites.

Detailed Summary

The Prostaglandin Inhibition for Emphysema (PIE) study will determine if a currently available therapy, ibuprofen 600 mg three times daily, can block PGE production in the lower respiratory tract and if this results in improvement in measures of lung repair function.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEmphysema
CountriesUnited States
CollaboratorsNational Jewish Health, Temple University, University of California, Los Angeles, University of Alabama at Birmingham

Timeline

Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedDec 10, 2013
Enrollment StartJan 1, 2014
Primary CompletionMar 31, 2018
TodayJul 2, 2026
Enrollment to primary: 4.3 yearsPosted 12.6 years ago

Interventions

600 mg ibuprofen three times daily for 48 weeksdrug

Placebo three times dailyother